Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene (This gene does not contain this module)
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: H1FX

Summary for H1FX

Gene information	Gene symbol	H1FX
	Ensembl ID	NA
	Entrez ID	NA
	Gene name	NA
	Synonyms	NA
	Gene type	NA
	UniProtAcc	NA

Top

Dataset with differentially expressed gene: H1FX

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	0.468659	4.87e-35
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	0.378169	0.00e+00
GSE131984_Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	NA	Malignant cells	-0.357299	2.22e-12
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Plasma cells	0.348041	2.29e-02
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	-0.29963	1.11e-21
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Progenitors	0.532433	1.09e-02
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.414287	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	-0.28767	1.01e-02
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-0.486663	3.45e-26
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	cDCs	0.512152	1.05e-04
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	0.368085	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	cDCs	0.26605	1.84e-02
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.261073	2.28e-43
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Plasma cells	-0.486801	2.83e-02
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD4+ T cells	-0.55502	2.22e-10
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	-0.651828	3.72e-02
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	-1.18209	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Erythrocytes	-0.8257	4.73e-37
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-0.624505	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.506844	1.22e-29
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	-0.261773	1.66e-04
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Plasma cells	0.40491	6.53e-05
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.924163	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	NK cells	0.420486	2.43e-06
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD8+ T cells	0.337004	1.17e-13
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	cDCs	0.746659	2.07e-04
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Mono/Macro	0.256484	6.44e-09
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Malignant cells	0.513472	9.91e-03
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Mono/Macro	0.873566	6.36e-41
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD8+ T cells	1.11993	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	-0.622506	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	-1.56588	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.852921	9.64e-36
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	-0.449226	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-1.12303	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	-0.613434	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Erythrocytes	-0.888669	4.79e-31
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.468928	1.41e-23
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	-0.61609	5.61e-35
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD8+ T cells	0.540962	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	NK cells	0.367523	3.35e-03
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD4+ T cells	0.761512	4.23e-05
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	B cells	0.638413	4.06e-02
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	0.371727	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Mono/Macro	0.33141	5.26e-11
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	B cells	0.286886	7.67e-03
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	0.475231	0.00e+00

Top

Expression of H1FX in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to H1FX

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating H1FX

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Top

Motifs and transcription factors (TFs) regulating H1FX

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
H1FX	metacluster_131.7	EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR2; EGR2; EGR2; EGR2; EGR2; EGR2; EGR3; EGR3; EGR3; EGR3; EGR3; EGR3; EGR4; EGR4; WT1 (directAnnotation). EGR1; EGR1; EGR1; EGR1; EGR1; EGR2; EGR2; EGR2; EGR2; EGR2; EGR3; EGR3; WT1; ZBTB43; ZBTB43; ZBTB43; ZBTB43; ZBTB5; ZBTB5; ZBTB5; ZBTB5; ZBTB7A; ZBTB7A; ZBTB7A; ZBTB7A; ZNF367; ZNF367; ZNF367; ZNF367; ZNF740; ZNF740; ZNF740; ZNF740 (inferredBy_Orthology).
H1FX	metacluster_131.4	EGR2; EGR2; ZFHX2; ZNF141 (directAnnotation).
H1FX	dbtfbs__GMEB1_K562_ENCSR928KOR_merged_N1	GMEB1 (directAnnotation).
H1FX	taipale_cyt_meth__CREB1_NRTGACGTN_eDBD_repr	CREB1 (directAnnotation).
H1FX	metacluster_111.3	ATF1; ATF3; CREB1; CREB1; CREB1; CREB1; CREB1; CREM; CREM; CREM; CREM; E4F1; E4F1 (directAnnotation). CREB1; CREB1; CREM; JDP2 (inferredBy_Orthology).
H1FX	jaspar__MA0604.1	ATF1 (inferredBy_Orthology).
H1FX	kznf__ZSCAN16_Schmitges2016_ChIP-seq	ZSCAN16 (directAnnotation).
H1FX	metacluster_71.5	HIF1A (directAnnotation).
H1FX	cisbp__M01802	XBP1 (inferredBy_Orthology).
H1FX	tfdimers__MD00380	ARID3A; ING4 (directAnnotation).
H1FX	cisbp__M01815	CEBPE (inferredBy_Orthology).
H1FX	taipale_tf_pairs__TEAD4_CLOCK_NCACGTGNNNNNNCATWCC_CAP_repr	CLOCK; TEAD4 (directAnnotation).
H1FX	transfac_pro__M07078	BHLHE40 (inferredBy_Orthology).
H1FX	tfdimers__MD00535	FOXG1; FOXO1; TFAP4 (directAnnotation).
H1FX	jaspar__MA1509.1	IRF6 (directAnnotation).
H1FX	tfdimers__MD00302	IRF7; IRF8 (directAnnotation).
H1FX	metacluster_155.6	ZNF212; ZNF785; ZSCAN4 (directAnnotation).
H1FX	transfac_pro__M03812	ARNT (directAnnotation).
H1FX	cisbp__M01720	ARNT2 (inferredBy_Orthology).
H1FX	cisbp__M01738	BHLHE40 (inferredBy_Orthology).
H1FX	metacluster_155.7	KLF8; ZSCAN1; ZSCAN1; ZSCAN4; ZSCAN4; ZSCAN4 (directAnnotation).
H1FX	metacluster_14.4	BHLHE40 (inferredBy_Orthology).
H1FX	metacluster_65.9	ZSCAN4 (directAnnotation).
H1FX	kznf__ZNF223_Imbeault2017_RP_ChIP-seq	ZNF223 (directAnnotation).
H1FX	taipale_cyt_meth__FOXG1_NAYRYAAACAN_eDBD	FOXG1 (directAnnotation).
H1FX	c2h2_zfs__M0404	ZFP3 (inferredBy_Orthology).
H1FX	taipale_tf_pairs__GCM1_MAX_NNCACGTGNNNGCGGGYN_CAP_repr	GCM1; MAX (directAnnotation).
H1FX	cisbp__M01719	ARNT (inferredBy_Orthology).
H1FX	swissregulon__hs__EPAS1	EPAS1 (directAnnotation).
H1FX	metacluster_14.18	BHLHE40 (directAnnotation).
H1FX	metacluster_122.4	CDC5L; ZNF382 (directAnnotation).
H1FX	kznf__ZBTB26_Schmitges2016_ChIP-seq	ZBTB26 (directAnnotation).
H1FX	metacluster_71.6	ARNT (directAnnotation).
H1FX	jaspar__MA1108.2	MXI1 (directAnnotation).
H1FX	tfdimers__MD00224	EOMES; YY2 (directAnnotation).
H1FX	homer__GGGGGTGTGTCC_KLF10	KLF10 (directAnnotation).
H1FX	metacluster_58.5	MSANTD3; MSANTD3; ZNF266; ZNF266 (directAnnotation).
H1FX	taipale_cyt_meth__MLX_NCAYGTGN_eDBD_meth	MLX (directAnnotation).
H1FX	cisbp__M01497	MAX (directAnnotation).
H1FX	kznf__ZNF805_Imbeault2017_OM_RCADE	ZNF805 (directAnnotation).
H1FX	cisbp__M00221	SNAI2 (directAnnotation).
H1FX	transfac_pro__M01029	MITF; TFE3; TFEB; TFEC (directAnnotation).
H1FX	taipale_cyt_meth__HES5_NCACACKY_eDBD_meth_repr	HES5 (directAnnotation).
H1FX	hdpi__INSM1	INSM1 (directAnnotation).
H1FX	tfdimers__MD00412	E2F6; NR3C1 (directAnnotation).
H1FX	homer__GGYAATGAAA_Hoxa10	HOXA10 (inferredBy_Orthology).
H1FX	hocomoco__ETV3_HUMAN.H11MO.0.D	ETV3 (directAnnotation).
H1FX	nitta__Ets98B_TTCCCC20NTA_KH_TKGCGGATGCN_m1_c3	SPDEF (inferredBy_Orthology).
H1FX	transfac_pro__M03575	NHLH2 (directAnnotation).
H1FX	metacluster_14.6	ARNTL; BHLHE40; BHLHE40; CLOCK (directAnnotation). ARNTL; BHLHE41 (inferredBy_Orthology).

Page: 1 2 3 4 5 6 7 8

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."